The Value of Programmed Death Ligand 1 Expression in Cancer Patients Treated with Neoadjuvant Chemotherapy

Journal Title: Sultan Qaboos University Medical Journal - Year 2019, Vol 19, Issue 4

Abstract

Programmed death ligand 1 (PD-L1) is an inhibitory molecule expressed by cancer cells to supress T-cell activity and escape anti-tumour immunity. The role of PD-L1 in cancer has been studied extensively as it is considered an important immune checkpoint against immune over-activation through its interaction with Programmed death receptor 1 (PD-1) expressed on activated lymphocytes. PD-L1 expression was found to be enhanced by chemotherapy through different proliferation pathways. However, the predictive and prognostic value for PD-L1 expression in cancer patients treated with neoadjuvant chemotherapy (NAC) is not yet established. This review focused on the potential effects of chemotherapy on PD-L1 expression and the role of PD-L1 as a prognostic and predictive marker in NAC-treated cancer patients. In addition, the potential use of this marker in clinical practice is discussed.

Authors and Affiliations

Malika Al-Dughaishi, Asem Shalaby, Khawla Al-Ribkhi, Ammar Boudaka, Mohamed-Rachid Boulassel, Jumana Saleh

Keywords

Related Articles

The Effect of Antepartum Depression on the Outcomes of Pregnancy and Development of Postpartum Depression: A prospective cohort study of Omani women

Objectives: This study aimed to identify the relationship between antenatal depression and pregnancy outcomes, including the risk of developing postpartum depression in Oman. Methods: This follow-up prospective longitudi...

Varied Presentations of Acute Glomerulonephritis in Children Single centre experience from a developing country

Te objective of this prospective study, carried out at Manipal Teaching Hospital, Pokhara, was to document the various clinical presentations of children with acute glomerulonephritis and compare them with the available...

Cushing’s Disease Sustained remission in fve cases induced by medical therapy with the dopamine agonist cabergoline

We report fve cases of Cushing’s disease where the patients were given a therapeutic trial of cabergoline. Morning serum cortisol, adrenocorticotrophic hormone (ACTH), and sleeping cortisol concentrations were signif...

Effectiveness and Needs Assessment of Faculty Development Programme for Medical Education: Experience from Saudi Arabia

Objectives: Faculty members are the most important resource in any institution of higher education as medical education has been, and continues to be, a priority for medical colleges in Saudi Arabia. This study aimed to...

Keystone Design Sliding Skin Flap for the Management of Small Full Thickness Burns

Deep dermal burns and full thickness burns are generally managed by excision and split thickness skin grafting. Te skin graft may lead to unacceptable colour changes and be aesthetically unacceptable. Also, there may b...

Download PDF file
  • EP ID EP675776
  • DOI http://dx.doi.org/10.18295/squmj.2019.19.04.002
  • Views 197
  • Downloads 0

How To Cite

Malika Al-Dughaishi, Asem Shalaby, Khawla Al-Ribkhi, Ammar Boudaka, Mohamed-Rachid Boulassel, Jumana Saleh (2019). The Value of Programmed Death Ligand 1 Expression in Cancer Patients Treated with Neoadjuvant Chemotherapy. Sultan Qaboos University Medical Journal, 19(4), -. https://europub.co.uk/articles/-A-675776